NewsLincoln Pharmaceuticals Limited Confirms Non-Large Corporate Status Under SEBI Framework for FY 2026-27Lincoln Pharmaceuticals Limited Confirms Non-Large Corporate Status Under SEBI Framework for FY 2026-27
Lincoln Pharmaceuticals Limited has notified stock exchanges that it does not qualify as a Large Corporate under SEBI's regulatory framework for FY 2026-27. The company submitted its mandatory disclosure on April 16, 2026, confirming that criteria such as outstanding borrowing and credit rating thresholds do not apply to its operations. The disclosure was properly executed by Company Secretary Trusha Shah and CFO Darshit Shah, demonstrating compliance with SEBI circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.
*this image is generated using AI for illustrative purposes only.
Lincoln Pharmaceuticals Limited has officially informed stock exchanges that it does not qualify as a Large Corporate under the SEBI regulatory framework for FY 2026-27. The Ahmedabad-based pharmaceutical company submitted its mandatory disclosure to both the National Stock Exchange of India Limited and BSE Limited on April 16, 2026.
Regulatory Compliance Disclosure
The company's disclosure references SEBI Circular No: SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, which establishes the framework for Large Corporate classification. Lincoln Pharmaceuticals confirmed that the specified criteria outlined in the circular are not applicable to the company as of March 31, 2026.
| Parameter | Status |
|---|---|
| Outstanding Borrowing as of March 31: | Not applicable |
| Highest Credit Rating during Previous FY: | Not applicable |
| Stock Exchange for Fine Payment: | Not applicable |
| Large Corporate Classification: | Does not qualify |
Official Documentation
The disclosure was formally signed by key company officials, demonstrating proper corporate governance compliance:
- Trusha Shah - Company Secretary & Compliance Officer
- Darshit Shah - Chief Financial Officer
Both officials digitally signed the documents on April 16, 2026, with timestamps showing the CFO's signature at 14:14:24 +05'30' and the Company Secretary's signature at 14:48:20 +05'30'.
Company Information
Lincoln Pharmaceuticals Limited operates from its registered office at "Lincoln House," Science City Road, Sola, Ahmedabad-380 060, Gujarat. The company maintains manufacturing facilities at Trimul Estate, Near Khatraj Chokadi, in Gandhinagar district. The pharmaceutical company holds WHO-GMP certification and maintains various quality management system certifications.
Regulatory Framework Context
The SEBI circular dated October 19, 2023, requires entities to make initial disclosures within 30 days from the beginning of the financial year if they qualify as Large Corporates. Lincoln Pharmaceuticals' proactive disclosure confirms its compliance with regulatory requirements while clarifying its non-applicability under the Large Corporate framework for FY 2026-27.
Historical Stock Returns for Lincoln Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.98% | +6.02% | +1.60% | +16.55% | +6.28% | +149.13% |
What growth trajectory would Lincoln Pharmaceuticals need to achieve to potentially qualify as a Large Corporate in future financial years?
How might this non-Large Corporate status impact Lincoln Pharmaceuticals' access to capital markets and borrowing costs compared to larger peers?
Will Lincoln Pharmaceuticals' regulatory compliance requirements and reporting obligations differ significantly from Large Corporate entities in FY 2026-27?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
